Aberrant epigenetics in rheumatoid arthritis and osteoarthritis

Future Rheumatology

Volumn 2, Issue 3, 2007, Pages 257-260

  Lin, Hai Shu ^a   Baron, Roland ^b   Clement Lacroix, Philippe ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Galapagos   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDOHYDROLASE INHIBITOR; FR 235222; FR 901228; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PHENYLBUTYRIC ACID; PROTEIN P16; PROTEIN P21; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VORINOSTAT;

ADJUVANT ARTHRITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHONDROPATHY; COHORT ANALYSIS; DISEASE COURSE; DISEASE MODEL; DOWN REGULATION; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; METHODOLOGY; MOLECULAR MECHANICS; NONHUMAN; OSTEOARTHRITIS; PANNUS; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SAMPLE SIZE; SINGLE DRUG DOSE; SYNOVIUM; UPREGULATION; WESTERN BLOTTING;

EID: 34347377147     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.2.3.257     Document Type: Article

References (18)

1. Huber LC, Brock M, Hemmatazad H et al.: Histone deacetylase/ acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum. 56(4), 1087-1093 (2007).
2. Egger G, Liang G, Aparicio, A. Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990), 457-463 (2004).
3. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5(1), 37-50 (2006).
4. Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1(4), 287-299 (2002).
5. Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (9), 769-784 (2006).
6. Marks PA, Breslow R: Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25(1). 84-90 (2007).
7. Grant S, Easley C, Kirkpatrick P: Vorinostat. Nat. Rev. Drug Discov. 6(1). 21-22 (2007).
8. Marks PA: Discovery and development of SAHA as an anticancer agent. Oncogene 26(9), 1351-1356 (2007).
9. Ito K, Ito M, Elliott WM et al.: Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 352(19), 1967-1976 (2005).
10. Barnes PJ, Adcock IM, Ito K: Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 25(3), 552-563 (2005).
11. Adcock IM, Ito K, Barnes PJ: Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2 (4), 445-455 (2005).
12. Nishida K, Komiyama T, Miyazawa S et al.: Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p161NK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 50(10), 3365-3376 (2004).
13. Chung YL, Lee MY, Wang AJ, Yao LF: A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 8(5), 707-717 (2003).
14. Mori H, Abe F, Furukawa S et al.: FR235222, a fungal metabolite, is a novel Immunosuppressant that inhibits mammalian histone deacetylase (HDAC) II. Biological activities in animal models. J. Antibiot (Tokyo) 56(2), 80-86 (2003).
15. Lin HS, Hu CY, Chan HY et al.: Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150(7), 862-872 (2007).
16. Adcock IM: HDAC inhibitors as anti-inflammatory agents. Br. J. Pharmacol. 150(7), 829-831 (2007).
17. Adcock IM: Histone deacetylase inhibitors as novel anti-inflammatory agents. Curr. Opin. Investig. Drugs 7(11). 966-973 (2006).
18. Blanchard F, Chipoy C: Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov. Today 10(3), 197-204 (2005).